Estimates Revisions Telix Pharmaceuticals Limited Nasdaq
Stocks
TLX
US87961M1053
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 11.94 USD | +1.70% |
|
+5.76% | +59.41% |
| 09-02 | ASX Biggest Gainers | MT |
| 09-02 | Telix Pharmaceuticals Completes Patient Enrollment for Phase 3 Study of Imaging Agents in Prostate Cancer | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- TLX Stock
- TLX Stock
- Consensus Telix Pharmaceuticals Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
